Price$211.77+30.36 (+16.74%)
2026-06-162026-09-18
News · 26 weeks78-84%
2026-03-292026-09-20
Mix3090d
- Insider20(67%)
- Other4(13%)
- Earnings2(7%)
- SEC Filings2(7%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRIntegrated DNA Technologies and Aldevron Launch New Cas9 mRNA Solutions to Accelerate Path from Gene Editing Research to DevelopmentCo-developed offering connects Integrated DNA Technologies’ CRISPR engineering and analysis expertise with Aldevron’s mRNA manufacturing capabilities, helping customers move from discovery toward clinical development with greater speed, continuity, and confidence.Research grade S.p. Cas9 mRNA is available in wild type and SpyFi™ high-fidelity formats to support CRISPR-based research applications.Optimized mRNA constructs are designed for high on-target editing, reduced off-target activity with SpyFi, low toxicity, and delivery method flexibility.Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and pr
- PRDanaher Announces Quarterly DividendWASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend
- ANALYSTUBS resumed coverage on Danaher with a new price targetUBS resumed coverage of Danaher with a rating of Buy and set a new price target of $250.00
- INSIDERPresident & CEO Blair Rainer sold $12,736,095 worth of shares (58,255 units at $218.63) (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERExecutive Vice President Riley Christopher Paul was granted 41,072 shares, increasing direct ownership by 201% to 61,472 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Financial Officer Gugino Matthew E4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by SVP-Chief Legal Officer Leiken Jonathan4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 13,477 shares, increasing direct ownership by 71% to 32,495 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Sawyer Montgomery Julie A4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by VP, Chief Accounting Officer Bouda Christopher4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERExecutive Vice President Milosevich Gregory M was granted 15,402 shares, increasing direct ownership by 170% to 24,467 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERChairman of Exec. Committee Rales Mitchell P was granted 500,000 shares, increasing direct ownership by 939% to 553,228 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERChairman Rales Steven M was granted 500,000 shares, increasing direct ownership by 16% to 3,605,808 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Zerhouni Elias A.4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Filler Linda4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Sanders A Shane4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Dewan Feroz4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Spoon Alan G4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director List Teri4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- INSIDERSEC Form 4 filed by Director Stevens Raymond C4 - DANAHER CORP /DE/ (0000313616) (Issuer)
- SECDanaher Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events8-K - DANAHER CORP /DE/ (0000313616) (Filer)
- PRDanaher Appoints Julie Sawyer Montgomery as President and Chief Executive OfficerRainer Blair to retireWASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026. On that date, Rainer Blair will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition. "In alignment with the Board of Directors' succession planning process, I am pleased to announce the appointment of Julie as our next Chief Executive Officer," said Steven Rales, Chairman of the Board of Directors of Danaher. "We are at a uniquely opportune mo
- SECDanaher Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DANAHER CORP /DE/ (0000313616) (Filer)
- PRDanaher Reports Second Quarter 2026 ResultsWASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Second Quarter 2026 ResultsNet earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94.Revenues increased 5.5% year-over-year to $6.3 billion.Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year.Operating cash flow was $1.5 billion an
- INSIDERVP, Chief Accounting Officer Bouda Christopher covered exercise/tax liability with 60 shares, decreasing direct ownership by 0.65% to 9,107 units (SEC Form 4)4 - DANAHER CORP /DE/ (0000313616) (Issuer)
DHR FAQ
7 questionsWhat does Danaher Corporation do?
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and...Where does DHR stock trade?
Danaher Corporation (DHR) is listed on NYSE.What sector and industry is DHR in?
Danaher Corporation operates in the Industrials sector, Industrial Machinery/Components industry.Does DHR pay a dividend?
Yes. DHR's next ex-dividend date is 2026-09-30 with a declared cash dividend of $0.40 per share, payable 2026-10-30.What are analysts saying about DHR?
Danaher Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to DHR?
Notable peers in the same industry include ASML (ASML Holding N.V. New York Registry Shares), LRCX (Lam Research Corporation), TMO (Thermo Fisher Scientific Inc), DE (Deere & Company), ETN (Eaton Corporation PLC). Compare DHR side-by-side with any of them on Quantisnow.How can I track DHR on Quantisnow?
Quantisnow aggregates Danaher Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DHR to receive live email and push alerts on every new disclosure.